Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Administrative data

Endpoint:
basic toxicokinetics
Type of information:
other: theoretical assessment
Adequacy of study:
key study
Study period:
2013
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: A theoretical assessment, non-GLP, based on the REACH guidance IR CSA, R.7, has been performed.

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
2013
Report date:
2013

Materials and methods

Principles of method if other than guideline:
Expert statement based on the (physico-chemical) properties of the substance.
GLP compliance:
no

Test material

Constituent 1
Reference substance name:
Dodecene, hydroformylation products, low-boiling
EC Number:
271-240-3
EC Name:
Dodecene, hydroformylation products, low-boiling
Cas Number:
68526-92-1
Molecular formula:
The substance consists of 46 isomers of unsaturated and branched dodecene structures (see Test Report No. A170002983).
IUPAC Name:
Dodecene, hydroformylation products, low-boiling
Test material form:
other: liquid

Results and discussion

Main ADME results
Type:
absorption
Results:
For risk assessment purposes absorption factors for Oxooil LS13 are derived to be 50% (oral), 100% (inhalation) and 50% (dermal).

Applicant's summary and conclusion

Conclusions:
Interpretation of results (migrated information): other: Based on its lipophilic characteristics (log Pow of 7.6-8.3) and its low water solubility (≤ 1.2mg/L at 20 °C), the bioaccumulation potential is expected to be high.
Based on its physical/chemical properties, absorption factors for Oxooil LS13 are derived to be 50% (oral), 100% (inhalation) and 50% (dermal) for risk assessment purposes.
Based on its lipophilic characteristics (log Pow of 7.6-8.3) and its low water solubility (≤ 1.2mg/L at 20 °C), the bioaccumulation potential is expected to be high.